U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. Science and Research Special Topics
  4. External Peer Review (Letter) of Safety of CBD in Humans - A Literature Review conducted on publicly available data through [December 12, 2019]
  1. Science and Research Special Topics

External Peer Review (Letter) of Safety of CBD in Humans - A Literature Review conducted on publicly available data through [December 12, 2019]

Title of the Review:
External Peer Review (Letter) of Safety of CBD in Humans - A Literature Review conducted on publicly available data through [December 12, 2019]

Tentative Assessment:
Influential Scientific Information

Agency Contact:
April Alexandrow

Office or Center:
Office of the Commissioner, Office of Clinical Policy & Programs (OCPP)

Subject of the Review:
Cannabidiol (CBD)

Purpose of the Review:
Conduct an expert peer review

Type of Review:
Individual Reviews (Letter Review)

Timing of Review:
Within approximately 30 – 90 days after posting of this peer review plan

Number of Reviewers:
4-10

Primary Disciplines:
At least one expert in each of the following disciplines: biology and life sciences; pharmacology; toxicology; epidemiology; and medical or clinical

Types of Expertise of Reviewers:  

Reviewers Selected by:
Designated Outside Organization

Opportunities for the Public to Comment:
No

If yes, briefly state how and when will these opportunities be provided:

Peer Reviewers Provided with Public Comments:
No

Back to Top